Soleno Therapeutics (SLNO) Competitors $83.67 -2.09 (-2.44%) As of 02:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SLNO vs. FEMY, IMVT, SNN, SOLV, PEN, STVN, IRTC, GKOS, BLCO, and TMDXShould you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), and TransMedics Group (TMDX). These companies are all part of the "medical" sector. Soleno Therapeutics vs. Its Competitors Femasys Immunovant Smith & Nephew SNATS Solventum Penumbra Stevanato Group iRhythm Technologies Glaukos Bausch + Lomb TransMedics Group Femasys (NASDAQ:FEMY) and Soleno Therapeutics (NASDAQ:SLNO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk. Do analysts prefer FEMY or SLNO? Femasys presently has a consensus price target of $7.33, suggesting a potential upside of 881.70%. Soleno Therapeutics has a consensus price target of $113.30, suggesting a potential upside of 35.54%. Given Femasys' higher probable upside, equities research analysts clearly believe Femasys is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Which has more risk & volatility, FEMY or SLNO? Femasys has a beta of -2.58, suggesting that its stock price is 358% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -2.56, suggesting that its stock price is 356% less volatile than the S&P 500. Does the media prefer FEMY or SLNO? In the previous week, Soleno Therapeutics had 10 more articles in the media than Femasys. MarketBeat recorded 18 mentions for Soleno Therapeutics and 8 mentions for Femasys. Soleno Therapeutics' average media sentiment score of 0.95 beat Femasys' score of 0.32 indicating that Soleno Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Femasys 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Soleno Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in FEMY or SLNO? 65.3% of Femasys shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 11.5% of Femasys shares are owned by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has higher valuation and earnings, FEMY or SLNO? Femasys has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFemasys$1.63M14.91-$18.82M-$0.86-0.87Soleno TherapeuticsN/AN/A-$175.85M-$4.14-20.19 Is FEMY or SLNO more profitable? Soleno Therapeutics has a net margin of 0.00% compared to Femasys' net margin of -1,113.72%. Soleno Therapeutics' return on equity of -73.74% beat Femasys' return on equity.Company Net Margins Return on Equity Return on Assets Femasys-1,113.72% -613.84% -152.63% Soleno Therapeutics N/A -73.74%-56.67% SummarySoleno Therapeutics beats Femasys on 10 of the 16 factors compared between the two stocks. Get Soleno Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLNO vs. The Competition Export to ExcelMetricSoleno TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.45B$2.42B$5.49B$9.81BDividend YieldN/A1.78%4.59%4.13%P/E Ratio-20.2021.1529.9725.18Price / SalesN/A677.26444.82102.90Price / CashN/A23.6624.8128.01Price / Book14.725.268.695.83Net Income-$175.85M$31.61M$3.26B$265.22M7 Day Performance2.40%-0.18%0.45%0.77%1 Month Performance2.48%1.78%3.13%1.99%1 Year Performance78.46%6.35%45.69%27.37% Soleno Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNOSoleno Therapeutics4.5819 of 5 stars$83.59-2.5%$113.30+35.5%+86.8%$4.45BN/A-20.2030Earnings ReportAnalyst RevisionFEMYFemasys3.4441 of 5 stars$0.81-1.4%$8.67+972.2%-16.6%$26.29M$1.63M-0.8930News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastGap UpIMVTImmunovant2.2704 of 5 stars$16.09+2.4%$36.40+126.2%-49.5%$2.75BN/A-5.87120News CoverageEarnings ReportAnalyst ForecastSNNSmith & Nephew SNATS2.4911 of 5 stars$30.79-0.1%$28.00-9.1%+20.4%$13.49B$5.81B14.2617,349Dividend CutSOLVSolventum2.2402 of 5 stars$73.24+2.1%$84.38+15.2%+18.6%$12.67B$8.31B33.9122,000Earnings ReportPENPenumbra4.6508 of 5 stars$240.71-0.9%$300.47+24.8%+41.0%$9.39B$1.19B64.024,500Positive NewsSTVNStevanato GroupN/A€25.58+1.8%N/A+8.6%€7.75B€1.19B50.165,521Positive NewsIRTCiRhythm Technologies1.9592 of 5 stars$164.98+0.0%$157.30-4.7%+126.2%$5.30B$591.84M-56.312,000GKOSGlaukos3.9692 of 5 stars$87.52+1.6%$127.42+45.6%-28.5%$5.00B$383.48M-53.04780Positive NewsBLCOBausch + Lomb2.8341 of 5 stars$13.76+1.9%$15.56+13.0%-13.2%$4.87B$4.89B-17.6413,500TMDXTransMedics Group2.3393 of 5 stars$128.50+6.6%$123.00-4.3%-21.9%$4.38B$531.29M66.58210 Related Companies and Tools Related Companies Femasys Alternatives Immunovant Alternatives Smith & Nephew SNATS Alternatives Solventum Alternatives Penumbra Alternatives Stevanato Group Alternatives iRhythm Technologies Alternatives Glaukos Alternatives Bausch + Lomb Alternatives TransMedics Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLNO) was last updated on 8/12/2025 by MarketBeat.com Staff From Our Partners#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access